title: Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.
abstract: To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<or=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >or=30%, and a $100 vaccine at vaccine efficacy >or=70%. High MRSA prevalence (>or=25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.
authors.affiliation: Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh, Pittsburgh, PA, USA. BYL1@pitt.edu <BYL1@pitt.edu>
authors.forename: Bruce Y
authors.initials: BY
authors.lastname: Lee
authors.forename: Ann E
authors.initials: AE
authors.lastname: Wiringa
authors.forename: Rachel R
authors.initials: RR
authors.lastname: Bailey
authors.forename: G Jonathan
authors.initials: GJ
authors.lastname: Lewis
authors.forename: Jared
authors.initials: J
authors.lastname: Feura
authors.forename: Robert R
authors.initials: RR
authors.lastname: Muder
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000276:immunology*; D015233:Models, Statistical; D009985:Orthopedics; D011300:Preoperative Care / Q000191:economics* / Q000379:methods*; D013203:Staphylococcal Infections / Q000191:economics / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000191:economics* / Q000276:immunology*; D013530:Surgical Wound Infection / Q000191:economics / Q000517:prevention & control*
chemical_list: D013209:Staphylococcal Vaccines